公司资料
Natera 股价、新闻与催化剂
- 股票代码:
- NTRA
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
366.31 USD (+6.07%)
收盘价
最后更新: 2026年9月17日
30.5B USD
市值
股价为何变动
截至 2026年9月17日，NTRA 上涨 6.07%，收于 $366.31。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
业务概览
Natera is a molecular diagnostics company focused on cell-free DNA testing across oncology, women's health, and organ health.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ, Natera sits in precision diagnostics rather than therapeutics.
商业模式特征
The business is driven by test volume, reimbursement, and the expansion of its oncology and reproductive-testing franchises.
生物医药行业定位
Natera occupies a top-tier diagnostics niche because its platform can scale across multiple clinical use cases.
未来催化剂
- Natera’s catalysts are Signatera reimbursement, Prospera adoption, and continued MRD-platform penetration. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.
近期新闻
新闻标题由机器翻译，详情为英文原文。
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。